Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2019

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants further shift the complicated treatment algorithm. Roche / Genentech’s Ocrevus, Merck Serono’s Mavenclad, and a growing array of next-generation compounds from Novartis, Celgene, Actelion/Janssen, Biogen, Genmab, and TG Therapeutics will intensify competition in the saturated relapsing MS market. Meanwhile, Ocrevus continues to transform treatment in the underserved PP-MS population, and developers like MediciNova (with its intriguing candidate ibudilast) and Biogen (opicinumab) have renewed their focus on developing neuroprotective or reparative treatments in MS—now the “next frontier” in a market replete with reliable anti-inflammatory options. Separately, the looming entry of oral generics will introduce a new variable in this high-cost market as reimbursement authorities race to rein in healthcare costs. Understanding these intersecting forces will be key to the success of current and future players in this evolving market.

Questions Answered:

•  What is the commercial outlook for Ocrevus, Mavenclad, next-generation fumarates, and S1P receptor modulators in the competitive relapsing MS space, and where will they fit into an evolving treatment algorithm?
• What impact will Ocrevus and ibudilast have in the progressive MS market?
• What clinical roles will entrenched platform injectables, current and next-generation orals, and MAbs play in the evolving MS treatment algorithm?
• How will generic competition shape the MS market?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other DRG research.

Epidemiology: Diagnosed prevalence of MS by country, segmented by CIS, RR-MS, SP-MS, and PP-MS; drug-treated cases.

Emerging therapies: Phase II: 9 drugs; Phase III/preregistration: 10 drugs; coverage of select Phase I products.

Market forecast features: Patient-based market forecast extending through 2028, segmented by brands/generics.

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.